Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
New approaches in the management of multiple sclerosis.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Santhera to discontinue sale of Catena® in Canada
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Phase 3 Study of RPC1063 in Relapsing MS
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
US court permits generic version of Teva MS drug a year sooner
Pharmacology and therapeutic potential of interferons.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients

Pages